title: [The effect of thrombocyte-derived growth factor on experimental inflammatory bowel disease].
abstract: The role of Platelet-Derived Growth Factor (PDGF) was investigated in treatment of experimental inflammatory bowel disease (IBD) in animal models. A new model of IBD induced by the sulfhydryl (SH) alkylator iodoacetamide revealed that the most appropriate concentration of iodoacetamide is 6% given intracolonically once. Daily treatment with PDGF dose-dependently accelerated the healing of colonic erosions, ulcers and inflammation.
authors.affiliation: Department of Pathology Brigham Women's Hospital Harvard Medical School, Boston, USA.
authors.forename: Z
authors.initials: Z
authors.lastname: Sándor
authors.forename: S
authors.initials: S
authors.lastname: Kusstatscher
authors.forename: D
authors.initials: D
authors.lastname: Szeli
authors.forename: S
authors.initials: S
authors.lastname: Szabó
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced / Q000188:drug therapy*; D007460:Iodoacetamide / Q000494:pharmacology; D010982:Platelet-Derived Growth Factor / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D010982:Platelet-Derived Growth Factor; D007460:Iodoacetamide
vernacular_title: A thrombocyta eredetü növekedési faktor hatása kísérletes gyulladásos vastagbélbetegségben.